Company: MLTX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001821586-25-000022
Chunk: 3

Company: MoonLake Immunotherapeutics
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
813 $15 $1,828 Other comprehensive income— $— — $— $— $— $564 $564 $12 $576 Net loss for the three months ended June 30, 2024— $— — $— $— $(24,267)$— $(24,267)$(492)$(24,759)Balance at June 30, 202462,874,637 $6 995,267 $— $671,998 $(154,597)$3,256 $520,663 $9,368 $530,031 Share-based compensation under the Employee Share Participation Plan and MoonLake Immunotherapeutics 2022 Equity Incentive Plan— $— — $— $1,828 $— $— $1,828 $15 $1,843 Net loss for the three months ended September 30, 2024— $— — $— $— $(35,390)$— $(35,390)$(724)$(36,114)Other comprehensive loss— $— — $— $— $— $(432)$(432)$(9)$(441)Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares153,998 $— (153,998)$— $1,336 $— $9 $1,345 $(1,345)$— Options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan17,390 $— — $— $91 $— $— $91 $— $91 Refund of stamp duty fees for prior capital injection from MoonLake to MoonLake AG— $— — $— $90 $— $— $90 $2 $92 Balance at September 30, 202463,046,025 $6 841,269 $— $675,343 $(189,987)$2,833 $488,195 $7,307 $495,502 

The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

4

MOONLAKE IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS